This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Cardiac troponin biomarkers

Authoring team

The cardiac isoforms of Troponins I or T are the preferred markers for the diagnosis of myocardial injury. They are more sensitive and specific than than CK-MB or other conventional markers.

Troponins are present in complexes of similar weight to CK-MB and it is likely that they are released from injured cells at similar rates. Once elevated troponins may persist for a number of weeks and in some circumstances CK-MB may be useful in clarifying whether an event is recent (within 48 hours).

The ideal time to check for cardiac troponins is between 6 and 9 hours. Ideally one should also document an elevation in more than one sample

High sensitivity cardiac troponins (hs-cTnTs) can be taken earlier to determine if an acute myocardial infarction has occurred

  • there is evidence that using hs-cTnT determination, it was possible to diagnose an acute myocardial infarction in 94% of cases at admission and in 100% of the cases, if the assay was repeated at 3 h.

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.